XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.1

Segment Data (Tables)

6 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Area

Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.

			Three Months Ended March 31,
(Millions of dollars)			2023																		2022
			United States						International						Total						United States						International						Total
Medical
Medication Delivery Solutions (a)			$	616					$	454					$	1,070					$	590					$	460					$	1,049
Medication Management Solutions			550						173						723						461						143						604
Pharmaceutical Systems (a)			173						394						567						125						375						501
Total segment revenues			$	1,339					$	1,022					$	2,360					$	1,176					$	978					$	2,154
Life Sciences
Integrated Diagnostic Solutions			$	422					$	466					$	888					$	618					$	532					$	1,150
Biosciences			159						228						386						129						206						335
Total segment revenues			$	581					$	694					$	1,275					$	747					$	738					$	1,485
Interventional
Surgery			$	295					$	86					$	381					$	268					$	72					$	340
Peripheral Intervention			256						213						468						240						210						450
Urology and Critical Care			263						74						336						239						82						320
Total segment revenues			$	813					$	373					$	1,186					$	746					$	364					$	1,111
Total revenues from continuing operations			$	2,733					$	2,088					$	4,821					$	2,669					$	2,081					$	4,750

(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.

			Six Months Ended March 31,
(Millions of dollars)			2023																		2022
			United States						International						Total						United States						International						Total
Medical
Medication Delivery Solutions (a)			$	1,235					$	873					$	2,109					$	1,210					$	936					$	2,146
Medication Management Solutions			1,114						316						1,430						945						286						1,231
Pharmaceutical Systems (a)			292						684						976						228						669						897
Total segment revenues			$	2,642					$	1,873					$	4,515					$	2,383					$	1,892					$	4,274
Life Sciences
Integrated Diagnostic Solutions			$	930					$	911					$	1,841					$	1,232					$	1,062					$	2,295
Biosciences			296						440						736						258						416						674
Total segment revenues			$	1,226					$	1,351					$	2,577					$	1,490					$	1,478					$	2,968
Interventional
Surgery			$	582					$	162					$	744					$	549					$	152					$	701
Peripheral Intervention			492						410						902						457						407						863
Urology and Critical Care			522						148						670						492						168						661
Total segment revenues			$	1,595					$	720					$	2,315					$	1,498					$	727					$	2,225
Total Company revenues from continuing operations			$	5,462					$	3,944					$	9,407					$	5,372					$	4,096					$	9,468

(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.

Financial Information for Company's Segments

Segment income for the three and six-month periods was as follows:

			Three Months Ended March 31,												Six Months Ended March 31,
(Millions of dollars)			2023						2022						2023						2022
Income from Continuing Operations Before Income Taxes
Medical (a)			$	641					$	476					$	1,195					$	1,048
Life Sciences			394						475						827						1,009
Interventional			297						280						598						544
Total Segment Operating Income			1,333						1,231						2,621						2,602
Acquisition-related integration and restructuring expense			(62)						(28)						(106)						(62)
Net interest expense			(108)						(95)						(204)						(191)
Other unallocated items (b)			(635)						(665)						(1,301)						(1,307)
Total Income from Continuing Operations Before Income Taxes			$	529					$	442					$	1,009					$	1,041

(a)The amounts for the three and six months ended March 31, 2022 include a charge of $54 million recorded to Cost of products sold to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit, as well as a charge of $35 million to adjust estimated future product remediation costs.

(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration